Switch theme
Sign up to access all valuation multiples
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
1996
327
LTM Revenue $3.1M
LTM EBITDA -$300M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Xenon Pharmaceuticals has a last 12-month revenue (LTM) of $3.1M and a last 12-month EBITDA of -$300M.
In the most recent fiscal year, Xenon Pharmaceuticals achieved revenue of n/a and an EBITDA of -$277M.
Xenon Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Xenon Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $3.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$300M | XXX | -$277M | XXX | XXX | XXX |
| EBITDA Margin | -9790% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$305M | XXX | -$279M | XXX | XXX | XXX |
| EBIT Margin | -9947% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$269M | XXX | -$234M | XXX | XXX | XXX |
| Net Margin | -8755% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Xenon Pharmaceuticals's stock price is $29.
Xenon Pharmaceuticals has current market cap of $2.2B, and EV of $1.7B.
See Xenon Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7B | $2.2B | XXX | XXX | XXX | XXX | $-3.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Xenon Pharmaceuticals has market cap of $2.2B and EV of $1.7B.
Xenon Pharmaceuticals's trades at n/a EV/Revenue multiple, and -6.0x EV/EBITDA.
Equity research analysts estimate Xenon Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Xenon Pharmaceuticals has a P/E ratio of -8.2x.
See valuation multiples for Xenon Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV/Revenue | 544.9x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -5.6x | XXX | -6.0x | XXX | XXX | XXX |
| EV/EBIT | -5.5x | XXX | -6.0x | XXX | XXX | XXX |
| EV/Gross Profit | 544.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -8.2x | XXX | -9.4x | XXX | XXX | XXX |
| EV/FCF | -6.8x | XXX | -9.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialXenon Pharmaceuticals's last 12 month revenue growth is 306%
Xenon Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.9M for the same period.
Xenon Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Xenon Pharmaceuticals's rule of X is -9027% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Xenon Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 306% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -9790% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -9027% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xenon Pharmaceuticals acquired XXX companies to date.
Last acquisition by Xenon Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Xenon Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Xenon Pharmaceuticals founded? | Xenon Pharmaceuticals was founded in 1996. |
| Where is Xenon Pharmaceuticals headquartered? | Xenon Pharmaceuticals is headquartered in United States of America. |
| How many employees does Xenon Pharmaceuticals have? | As of today, Xenon Pharmaceuticals has 327 employees. |
| Who is the CEO of Xenon Pharmaceuticals? | Xenon Pharmaceuticals's CEO is Mr. Ian C. Mortimer. |
| Is Xenon Pharmaceuticals publicy listed? | Yes, Xenon Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Xenon Pharmaceuticals? | Xenon Pharmaceuticals trades under XENE ticker. |
| When did Xenon Pharmaceuticals go public? | Xenon Pharmaceuticals went public in 2014. |
| Who are competitors of Xenon Pharmaceuticals? | Similar companies to Xenon Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Xenon Pharmaceuticals? | Xenon Pharmaceuticals's current market cap is $2.2B |
| What is the current revenue of Xenon Pharmaceuticals? | Xenon Pharmaceuticals's last 12 months revenue is $3.1M. |
| What is the current revenue growth of Xenon Pharmaceuticals? | Xenon Pharmaceuticals revenue growth (NTM/LTM) is 306%. |
| What is the current EV/Revenue multiple of Xenon Pharmaceuticals? | Current revenue multiple of Xenon Pharmaceuticals is 544.9x. |
| Is Xenon Pharmaceuticals profitable? | Yes, Xenon Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Xenon Pharmaceuticals? | Xenon Pharmaceuticals's last 12 months EBITDA is -$300M. |
| What is Xenon Pharmaceuticals's EBITDA margin? | Xenon Pharmaceuticals's last 12 months EBITDA margin is -9790%. |
| What is the current EV/EBITDA multiple of Xenon Pharmaceuticals? | Current EBITDA multiple of Xenon Pharmaceuticals is -5.6x. |
| What is the current FCF of Xenon Pharmaceuticals? | Xenon Pharmaceuticals's last 12 months FCF is -$244M. |
| What is Xenon Pharmaceuticals's FCF margin? | Xenon Pharmaceuticals's last 12 months FCF margin is -7965%. |
| What is the current EV/FCF multiple of Xenon Pharmaceuticals? | Current FCF multiple of Xenon Pharmaceuticals is -6.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
